Evista (chemical name: raloxifene) is a SERM approved by the U.S. Food and Drug Administration (FDA) to: 1  reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women who haven't been diagnosed but are at higher-than-average risk for disease.
Types of paper ICT Express publishes original research papers in English in the fields of ICT convergence, platform technologies, communication networks, and device technologies. ICT Express accepts short-length (up to 4 pages in double columns and additional 2 pages will be allowed with over page charge (100USD/1page)) high-quality, original articles in Latex or Word format. Sample manuscript can be downloaded here.
PCT applications are typically published after the expiration of 18 months from the priorty date of that application (see: http://www.wipo.int/pct/en/texts/articles/a21.htm#_21). Thus, if a PCT application has been filed (and not withdrawn prior to publication) with a priority date of April XX, 2011, it will likely be published on: 1. October XX, 2011, if that day is a Thursday and not a official holiday for WIPO;